Oral semaglutide, sold as Rybelsus, has had the oral GLP1 space mostly to itself for a while. That just changed. A new head to head trial gives Eli Lilly's orforglipron, its own once daily pill, a real claim to being the stronger option, at least on the numbers, and at least so far.
The trial, called ACHIEVE 3, followed 1,698 adults with type 2 diabetes across six countries for 52 weeks, comparing orforglipron head to head against oral semaglutide. It's the first direct trial pitting the two oral GLP1 drugs against each other, published in The Lancet and reported independently by an academic at the University of Surrey not affiliated with Lilly.
From a starting average HbA1c of 8.3%, orforglipron brought it down by 1.71 to 1.91 percentage points over the year, compared with 1.47 points for oral semaglutide. It also produced more weight loss, 6.1 to 8.2 kg versus 5.3 kg. Orforglipron met its goal of performing at least as well as oral semaglutide, then beat it outright on both measures. The catch is tolerability: 59% of people on orforglipron had GI side effects versus 37 to 45% on oral semaglutide, and 10% dropped out compared with 4 to 5%, likely because orforglipron produces sharper daily peaks in drug concentration.
This is one industry sponsored trial, funded and run by Eli Lilly, the maker of orforglipron, and it hasn't been independently replicated yet. It was also conducted only in adults with type 2 diabetes, not the broader weight loss only population most of the current orforglipron interest is coming from, those trials are still ongoing. There's no head to head trial yet against injectable GLP1s either. None of this means the numbers are wrong, but a single company funded trial in one population is a real limit worth knowing before treating this as settled.
If you're already choosing between GLP1 pills, or waiting to see what becomes available, this trial suggests the real decision may come down to tolerability rather than raw efficacy, since orforglipron's edge in blood sugar and weight loss comes with a real bump in GI side effects and people dropping out. It's also a genuinely practical shift if orforglipron eventually reaches the market broadly: as a small molecule rather than a peptide, it could end up cheaper and easier to distribute, including in places without reliable refrigeration.
Not yet. This trial was run in adults with type 2 diabetes, and separate trials testing orforglipron purely for weight loss are still ongoing. It has not been approved by the FDA for either use as of this writing.
On the numbers in this one trial, yes, it lowered blood sugar and produced more weight loss. But it also came with more GI side effects and a higher dropout rate, so it is a real tradeoff rather than a clean win, and tolerability may end up mattering more to most people than the efficacy edge.
No, and that is one of the more practically interesting parts of this story. Orforglipron is a small molecule rather than a peptide, which means it is cheaper to manufacture, does not need refrigeration, and skips the empty stomach, thirty minute wait ritual that oral semaglutide requires.
Get the Daily Signal in your inbox each morning, verified and no hype, before you even open your phone.